Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group. Eto M, et al. Among authors: fujii y. Cancer Sci. 2014 Dec;105(12):1576-83. doi: 10.1111/cas.12546. Epub 2014 Nov 25. Cancer Sci. 2014. PMID: 25283266 Free PMC article. Clinical Trial.
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y, Kamei Y, Takahashi S, Namazu K, Umeyama Y, Bycott P, Furuse J. Ioka T, et al. Among authors: fujii y. Jpn J Clin Oncol. 2015 May;45(5):439-48. doi: 10.1093/jjco/hyv011. Epub 2015 Feb 3. Jpn J Clin Oncol. 2015. PMID: 25647781 Free PMC article. Clinical Trial.
Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.
Minami Y, Minami H, Miyamoto T, Yoshimoto G, Kobayashi Y, Munakata W, Onishi Y, Kobayashi M, Ikuta M, Chan G, Woolfson A, Ono C, Shaik MN, Fujii Y, Zheng X, Naoe T. Minami Y, et al. Among authors: fujii y. Cancer Sci. 2017 Aug;108(8):1628-1633. doi: 10.1111/cas.13285. Epub 2017 Jun 19. Cancer Sci. 2017. PMID: 28556364 Free PMC article. Clinical Trial.
Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.
Kudo M, Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S. Kudo M, et al. Among authors: fujii y. Liver Cancer. 2018 May;7(2):148-164. doi: 10.1159/000484620. Epub 2017 Dec 8. Liver Cancer. 2018. PMID: 29888205 Free PMC article.
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M. Uemura M, et al. Among authors: fujii y. Cancer Sci. 2020 Mar;111(3):907-923. doi: 10.1111/cas.14294. Epub 2020 Feb 5. Cancer Sci. 2020. PMID: 31883418 Free PMC article. Clinical Trial.
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J. Kudo M, et al. Among authors: fujii y. Liver Cancer. 2021 Jun;10(3):249-259. doi: 10.1159/000514420. Epub 2021 Apr 7. Liver Cancer. 2021. PMID: 34239811 Free PMC article.
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Uemura H, Albiges L, Fujii Y, Umeyama Y, Wang J, Mariani M, Schmidinger M. Tomita Y, et al. Among authors: fujii y. ESMO Open. 2022 Apr;7(2):100450. doi: 10.1016/j.esmoop.2022.100450. Epub 2022 Apr 6. ESMO Open. 2022. PMID: 35397432 Free PMC article. Clinical Trial.
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y, Larkin J, Venugopal B, Haanen J, Kanayama H, Eto M, Grimm MO, Fujii Y, Umeyama Y, Huang B, Mariani M, di Pietro A, Choueiri TK. Tomita Y, et al. Among authors: fujii y. ESMO Open. 2022 Oct;7(5):100564. doi: 10.1016/j.esmoop.2022.100564. Epub 2022 Aug 28. ESMO Open. 2022. PMID: 36037566 Free PMC article. Clinical Trial.
4,444 results